Health Canada recalls Emerade epinephrine auto-injectors
Health Canada has issued a recall of the Emerade Epinephrine Auto-Injector due to possible device failure.
“Please return your Emerade auto-injector to your pharmacy as soon as possible to obtain a suitable replacement.” May 5 recall notice state. “If you experience a life-threatening allergic reaction (anaphylaxis) before obtaining a replacement, use a recalled emerald before seeking emergency medical attention.”
The recall covers all 0.3 mg and 0.5 mg Emerald autoinjectors distributed in Canada between April 2022 and May 2023. These devices are manufactured by Quebec-based pharmaceutical company Bausch Health.
Epinephrine auto-injectors, EpiPens (a trademark of another company), commonly known as EpiPens, are primarily used to treat severe and potentially life-threatening allergic reactions or anaphylaxis through rapid injections of adrenaline. used to
According to Health Canada, the recall was initiated “after testing by the company identified a potential risk that the auto-injector might not activate or could activate prematurely if dropped.” I was.
“If the auto-injector does not work, the patient will not receive the required amount of epinephrine, and symptoms of potentially life-threatening anaphylaxis may worsen,” the health agency explained. “Although no shortages of substitute products are expected, the division will continue to actively monitor the supply situation.”